赛默飞世尔：接近100亿美元收购临床试验软件公司Clario

Core Viewpoint - Thermo Fisher is reportedly close to acquiring clinical trial software company Clario for $10 billion, aligning with its strategy to enhance capabilities in clinical trial data management [1] Company Summary - Thermo Fisher's stock price saw a slight increase ahead of the news of the potential acquisition [1] - The acquisition is expected to be announced soon, although the terms may be subject to change [1] Industry Summary - The move reflects a broader trend in the industry towards consolidating capabilities in clinical trial data management [1]